A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Status:
Completed
Trial end date:
2020-03-10
Target enrollment:
Participant gender:
Summary
HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy
called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD). Non-ambulatory
and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to
receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month
period.